OliX Pharmaceuticals Inc
KOSDAQ:226950
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OliX Pharmaceuticals Inc
Accounts Receivables
OliX Pharmaceuticals Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Accounts Receivables
₩1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Receivables
₩2T
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accounts Receivables
₩123.7B
|
CAGR 3-Years
44%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accounts Receivables
₩80.8m
|
CAGR 3-Years
332%
|
CAGR 5-Years
141%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Receivables
₩37.2B
|
CAGR 3-Years
64%
|
CAGR 5-Years
81%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accounts Receivables
₩59.1B
|
CAGR 3-Years
2 371%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OliX Pharmaceuticals Inc
Glance View
OliX Pharmaceuticals, Inc. engages in the research and development of treatments and the manufacture and sale of new drugs. The company is headquartered in Suwon, Gyeonggi-Do and currently employs 72 full-time employees. The company went IPO on 2018-07-18. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The firm operates its business within domestic market and to overseas markets.
See Also
What is OliX Pharmaceuticals Inc's Accounts Receivables?
Accounts Receivables
1.1B
KRW
Based on the financial report for Dec 31, 2025, OliX Pharmaceuticals Inc's Accounts Receivables amounts to 1.1B KRW.
What is OliX Pharmaceuticals Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
91%
Over the last year, the Accounts Receivables growth was 11%. The average annual Accounts Receivables growth rates for OliX Pharmaceuticals Inc have been 10% over the past three years , 91% over the past five years .
